PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail

Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450 Alexandria, Virginia 22313-1450

or Fax (571) 273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for

maintenance fee notific							
CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)				Note: A certificate of Fee(s) Transmittal Tl	mailing can only be used for is certificate cannot be used to	or domestic mailings of the	
22840 7590	06/15/2011	06/15/2011			papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.		
GE HEALTHCARE BIO-SCIENCES CORP. PATENT DEPARTMENT 101 CARNEGIE CENTER PRINCETON, NJ 08540				Certificate of Mailing or Transmission I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.			
				MELISSA LECK		(Depositor's name)	
				/MELISSA LECK/		(Signature)	
				SEPTEMBER 13, 2011		(Date)	
APPLICATION NO.	FILING DATE	FIRST NAMED INVE		NTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/583,591	06/19/2006	Simon L. Stubb		os	PA0394	4011	
TITLE OF INVENTIO	N:						
CYTOCHROME C	PROTEIN AND ASSAY						
APPIN TYPE	APPLN. TYPE SMALL ENTITY ISSUE FEE		FE P	UBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE	
		<u> </u>			\$1810		
nonprovisional	· · · · · · · · · · · · · · · · · · ·		, , , , , , , , , , , , , , , , , , ,	\$300	\$1010 7	09/15/2011	
EXAMINER				CLASS-SUBCLASS			
MONSHIPOURI, MARYAM		1656		436-086000			
1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).			2. For printing on the patent front page, list (1) the names of up to 3 registered patent attorneys 1				
Change of corres	spondence address (or Change of SB/122) attached.	Correspondence	or agents OR, alto	ernatively,	•		
☐ "Fee Address" in	ndication (or "Fee Address" Indication (or more recent) attached. Us	tion form of a Customer 1 c		single firm (having as a member a y or agent) and the names of up to tattorneys or agents. If no name is 3			
3. ASSIGNEE NAME	AND RESIDENCE DATA TO I	BE PRINTED ON T	THE PATENT (print	or type)			
PLEASE NOTE: U recordation as set for	nless an assignee is identified borth in 37 CFR 3.11. Completion	elow, no assignee of this form is NO	data will appear on Γa substitute for fili	the patent. If an assigng an assignment.	nee is identified below, the d	ocument has been filed for	
(A) NAME OF ASS	SIGNEE	(B	B) RESIDENCE: (CITY and STATE OR COUNTRY)				
GE HEALTHCARE	UK LIMITED	L	LITTLE CHALFONT, GREAT BRITAIN				
Please check the appro	priate assignee category or catego	ories (will not be pr	inted on the patent):	☐ Individual	Corporation or other private gr	oup entity Government	
4a. The following fee(s) are enclosed: 4b. Payment of Fee							
☑ Issue Fee			A check in the amount of the fee(s) is enclosed.				
☑ Publication Fee (No small entity discount permitted)			☐ Payment by credit card. Form PTO-2038 is attached.				
☐ Advance Order - # of Copies			☐ The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number				
	tatus (from status indicated abov	*					
11	ms SMALL ENTITY status. See				LL ENTITY status. See 37 C		
NOTE: The Issue Fee a	PTO is requested to apply the Iss and Publication Fee (if required) e records of the United States Pa	will not be accepted	l from anyone other	than the applicant; a reg	y paid issue fee to the applica distered attorney or agent; or the	ne assignee or other party in	
Authorized Signature /ROYAL N. RONNING, JR./			Date SEPTEMBER 13, 2011				
Typed or printed name ROYAL N. RONNING, JR.			Registration No. <u>32529</u>				
This collection of infor an application. Confide submitting the complete this form and/or suggest	mation is required by 37 CFR 1. entiality is governed by 35 U.S.C ted application form to the USP	311. The information of the control	n is required to obtate 1.14. This collection depending upon the	in or retain a benefit by is estimated to take 12 individual case. Any coofficer, U.S. Patent and	the public which is to file (an minutes to complete, includin omments on the amount of ti	d by the USPTO to process) ag gathering, preparing, and me you require to complete artment of Commerce. P.O.	

Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
- 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.